ORAMED PHARMACEUTICALS INC.·4

Aug 21, 1:56 PM ET

Slager David Mark 4

4 · ORAMED PHARMACEUTICALS INC. · Filed Aug 21, 2017

Insider Transaction Report

Form 4
Period: 2017-08-17
Transactions
  • Exercise/Conversion

    Warrant (right to buy)

    2017-08-17$1.18/sh112,613$132,8380 total(indirect: By Regals Fund LP)
    Exercise: $3.77From: 2012-08-28Exp: 2017-08-28Common Stock (112,613 underlying)
  • Exercise/Conversion

    Common Stock

    2017-08-17$3.77/sh+112,613$424,0561,299,436 total(indirect: By Regals Fund LP)
Footnotes (3)
  • [F1]Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein.
  • [F2]The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
  • [F3]The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.

Documents

1 file
  • 4
    f4081717slager_oramendpharm.xmlPrimary

    OWNERSHIP DOCUMENT